We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Afriag | LSE:AFRI | London | Ordinary Share | IM00B3VVCM89 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.085 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
17 November 2020
AfriAg Global PLC
(‘AfriAg’ or the ‘Company’)
Apollon’s Stephen Barnhill at Prohibition Partners Live
AfriAg Global PLC (London AQSE: AFRI) is pleased to announce that Dr. Stephen Barnhill, Chairman of AfriAg’s RTO target, Apollon Formularies Ltd., will be speaking at 12:30 pm today at Prohibition Partners LIVE, the leading virtual cannabis conference.
Dr. Barnhill will be speaking as part of a panel, discussing the question ‘Is Personalised Medicine the Future of Cannabis?’, alongside industry leaders; Adrian Fischer, Managing Director of DEMECAN, Pat McCutcheon, CEO and Chairman of MediPharma Labs and David Babcock, CEO of Drug Science, as moderator.
Tickets to attend the conference can be found through the link below:
https://prohibitionpartners.live/tickets/
-ENDS-
For further information on AfriAg Global please visit the www.afriagglobal.com or please contact;
AfriAg Global Plc:
David Lenigas (Executive Chairman) +44 (0) 78821 825378
Peterhouse Capital Limited +44 (0) 20 7469 0930
Guy Miller
About Prohibition Partners LIVE:
Prohibition Partners LIVE is the leading virtual cannabis conference, connecting you to the international cannabis industry from anywhere in the world. This November 17th - 20th, Prohibition Partners LIVE is bringing together the global cannabis and psychedelics community for a virtual week
Copyright r 17 PR Newswire
1 Year Afriag Chart |
1 Month Afriag Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions